Xeris Biopharma Holdings, Inc. Ratios

Ratios Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
Gross Margin 54.35%73.14%79.47%82.52%81.86%
EBT Margin -446.54%-247.48%-87.15%-38.74%-28.12%
EBIT Margin -408.84%-232.22%-74.32%-26.85%-16.57%
EBITDA Margin -446.18%-247.55%-85.85%-37.98%-27.00%
Operating Margin -408.84%-232.22%-74.32%-26.85%-16.57%
Net Margin -446.00%-247.48%-85.86%-37.98%-27.00%
FCF Margin -396.06%-194.84%-93.33%-28.69%-18.21%
Efficiency
Inventory Average 13.24M21.43M31.79M43.51M
Assets Average 231.76M324.44M333.56M322.83M
Equity Average 64.50M70.21M19.20M-18.20M
Invested Capital 120.78M183.30M232.26M184.15M202.49M
Asset Utilization Ratio 0.210.340.490.63
Leverage & Solvency
Interest Coverage Ratio -7.81-15.99-5.81-1.65-1.10
Debt to Equity -30.97-7.84
Debt Ratio 0.650.72
Equity Ratio 0.210.310.13-0.02-0.09
Times Interest Earned -7.81-15.99-5.81-1.65-1.10
Valuation
Enterprise Value 107.18M262.96M58.89M252.14M433.77M
Market Capitalization 240.96M365.40M180.86M324.59M505.39M
Return Ratios
Return on Sales -4.46%-2.47%-0.86%-0.38%-0.27%
Return on Capital Employed -0.75%-0.33%-0.18%-0.15%
Return on Invested Capital -0.39%-0.21%-0.17%
Return on Assets -0.53%-0.29%-0.19%-0.17%
Return on Equity -1.90%-1.35%-3.24%3.01%